Equities analysts expect Agilent Technologies, Inc. (NYSE:A) to post $1.08 billion in sales for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Agilent Technologies’ earnings, with the highest sales estimate coming in at $1.08 billion and the lowest estimate coming in at $1.07 billion. Agilent Technologies reported sales of $1.04 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 3.8%. The firm is scheduled to announce its next earnings report on Wednesday, August 16th.

According to Zacks, analysts expect that Agilent Technologies will report full year sales of $1.08 billion for the current year, with estimates ranging from $4.37 billion to $4.42 billion. For the next financial year, analysts expect that the firm will post sales of $4.63 billion per share, with estimates ranging from $4.58 billion to $4.70 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Agilent Technologies.

Agilent Technologies (NYSE:A) last issued its earnings results on Monday, May 22nd. The medical research company reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.10. Agilent Technologies had a return on equity of 16.49% and a net margin of 13.41%. The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company posted $0.44 EPS. The firm’s revenue was up 8.1% compared to the same quarter last year.

A number of brokerages have weighed in on A. Robert W. Baird raised their target price on shares of Agilent Technologies from $57.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, May 24th. Jefferies Group LLC raised their target price on shares of Agilent Technologies from $59.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, May 23rd. Deutsche Bank AG raised their target price on shares of Agilent Technologies from $58.00 to $62.00 and gave the company a “buy” rating in a research note on Monday, May 22nd. Cowen and Company raised their target price on shares of Agilent Technologies from $53.00 to $62.00 and gave the company a “market perform” rating in a research note on Tuesday, May 23rd. Finally, Zacks Investment Research raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 target price for the company in a research note on Tuesday, May 16th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Agilent Technologies has an average rating of “Buy” and an average price target of $59.62.

Shares of Agilent Technologies (A) opened at 59.40 on Thursday. The company has a market capitalization of $19.09 billion, a price-to-earnings ratio of 33.39 and a beta of 1.25. The company has a 50-day moving average price of $58.32 and a 200-day moving average price of $52.30. Agilent Technologies has a 12 month low of $41.98 and a 12 month high of $61.15.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 26th. Investors of record on Monday, July 3rd will be given a dividend of $0.132 per share. This represents a $0.53 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Thursday, June 29th. Agilent Technologies’s dividend payout ratio (DPR) is currently 29.78%.

In related news, insider Patrick Kaltenbach sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 24th. The shares were sold at an average price of $54.50, for a total value of $109,000.00. Following the sale, the insider now owns 42,132 shares in the company, valued at $2,296,194. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Didier Hirsch sold 5,710 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $60.60, for a total transaction of $346,026.00. The disclosure for this sale can be found here. Insiders have sold 149,119 shares of company stock valued at $8,732,219 in the last three months.

A number of large investors have recently modified their holdings of the company. Nomura Asset Management Co. Ltd. boosted its stake in shares of Agilent Technologies by 1.6% in the first quarter. Nomura Asset Management Co. Ltd. now owns 39,220 shares of the medical research company’s stock valued at $2,073,000 after buying an additional 609 shares in the last quarter. Piedmont Investment Advisors LLC boosted its stake in shares of Agilent Technologies by 2,947.0% in the first quarter. Piedmont Investment Advisors LLC now owns 28,002 shares of the medical research company’s stock valued at $1,480,000 after buying an additional 27,083 shares in the last quarter. Skandinaviska Enskilda Banken AB publ boosted its stake in shares of Agilent Technologies by 5.7% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 64,834 shares of the medical research company’s stock valued at $3,428,000 after buying an additional 3,489 shares in the last quarter. Public Employees Retirement System of Ohio boosted its stake in shares of Agilent Technologies by 2.5% in the first quarter. Public Employees Retirement System of Ohio now owns 376,955 shares of the medical research company’s stock valued at $19,930,000 after buying an additional 9,139 shares in the last quarter. Finally, Achmea Investment Management B.V. bought a new stake in shares of Agilent Technologies during the first quarter valued at about $2,144,000.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/06/29/zacks-brokerages-expect-agilent-technologies-inc-a-will-announce-quarterly-sales-of-1-08-billion-2.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Get a free copy of the Zacks research report on Agilent Technologies (A)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.